

Our Ref: CPSU 164098N20JP
RFP Publication Ref: 021-6065/20
Publication Date: 02/06/20
Closing Date: 02/07/20

Request for Participation (Negotiation) for the Supply of Nilotinib 200mg capsules

Clarification No.1 – dated 11/06/20

Questions submitted by Economic Operators

Question 1: Reference is being made to the above RFP. We would appreciate if you can kindly advise for which indications and which age group nilotinib is procured for.

Answer 1: This medicine is being prescribed to adult and paediatric patients with chronic myelogenous leukaemia resistance or intolerance to prior therapy including imatinib as per SPC.

Question 2: Would you kindly clarify the reason why a direct negotiation has been issued for this item rather than issuing a RFP for a class since there is more than one option?

Answer 2: Nilotinib 200mg needs to be procured for patients stabilised on this treatment. As per DPA, for such cohort of patients, equivalents may be considered if evidence is submitted in order to verify that a proposed alternative medicine is interchangeable with Nilotinib 200mg tablets/capsules and that it is as effective and safe for use in stable patients to be switched over to the new product.

If there is competition, this process will be duly cancelled and a tender will be issued.

Kindly note that the deadline for submission of clarifications by economic operators is Friday, 26th June by noon.

The deadline for submission of clarification responses by the contracting authority is Monday, 29th June by noon.

The above clarifications are constituted to form an integral part of the original published procurement documentation.